drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR T cells)
drug_description
Autologous anti-CD19 CAR T-cell therapy with a 4-1BB costimulatory domain; engineered CD4+/CD8+ T cells recognize CD19 and kill malignant B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous CD4+/CD8+ T cells engineered with an anti‑CD19 CAR containing a 4‑1BB costimulatory domain bind CD19 on malignant B cells, triggering T‑cell activation, expansion, cytokine release, and perforin/granzyme‑mediated cytotoxic killing.
drug_name
Lisocabtagene maraleucel (liso-cel)
nct_id_drug_ref
NCT05672173